Source of Funding: This article is part of a supplement that was supported by Boehringer Ingelheim Pharmaceuticals, Inc. The authors ... nodules detected on CT images: from the Fleischner Society ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Boehringer Ingelheim (BI) and Click Therapeutics have announced they are expanding their collaboration to develop and commercialise a second prescription-based digital therapeutic (PDT) that will ...

Viking Therapeutics, Inc. stock has surged ... Pemvidutide, Boehringer Ingelheim/Zealand Therapeutics' Survodutide, Roche's (OTCQX:RHHBY) CT-388, and Zealand Pharma's Petrelintide, Eli Lilly's ...

Otsuka Pharma and Click Therapeutics' Rejoyn (formerly CT-152) app – which is used ... on DTx candidates for schizophrenia with Boehringer Ingelheim and with Indivior on software to support ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...